UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 572

Sortiert nach

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2384-2389

2008

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group

Journal of clinical oncology, 2006-08, Vol.24 (24), p.3844-3851

2006

Link zum Volltext

Verfügbarkeit prüfen

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1312-1318

2011

Link zum Volltext

Verfügbarkeit prüfen

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

Cancer medicine (Malden, MA), 2019-10, Vol.8 (14), p.6437-6448

2019

Link zum Volltext

Verfügbarkeit prüfen

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5182-5188

2009

Link zum Volltext

Verfügbarkeit prüfen

Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology Group

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1240-1246

2010

Link zum Volltext

Verfügbarkeit prüfen

Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group

Journal of clinical oncology, 2007-02, Vol.25 (4), p.362-369

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1304-1311

2011

Link zum Volltext

Verfügbarkeit prüfen

Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis

Cancer medicine (Malden, MA), 2023-05, Vol.12 (9), p.10222-10229

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2010-10, Vol.28 (30), p.4658-4663

2010

Link zum Volltext

Verfügbarkeit prüfen

Rhabdomyosarcoma: New Windows of Opportunity

The oncologist (Dayton, Ohio), 2005-08, Vol.10 (7), p.518-527

2005

Link zum Volltext

Verfügbarkeit prüfen

The significance of margins in pediatric Non‐Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)

Cancer medicine (Malden, MA), 2023-05, Vol.12 (10), p.11719-11730

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV

Journal of clinical oncology, 2003-01, Vol.21 (1), p.78-84

2003

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups

Pediatric blood & cancer, 2015-12, Vol.62 (12), p.2125-2131

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience—A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Journal of clinical oncology, 2007-11, Vol.25 (31), p.4909-4913

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2009-08, Vol.27 (22), p.3705-3711

2009

Link zum Volltext

Verfügbarkeit prüfen

Regarding Beau

Journal of clinical oncology, 2016-08, Vol.34 (22), p.2669-2670

Meyer, William H

2016

Link zum Volltext

Verfügbarkeit prüfen

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2016-01, Vol.34 (2), p.117-122

2016

Link zum Volltext

Verfügbarkeit prüfen

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial

The lancet oncology, 2020-08, Vol.21 (8), p.1110-1122

2020

Link zum Volltext

Verfügbarkeit prüfen

Pooled Analysis of Phase II Window Studies in Children With Contemporary High-Risk Metastatic Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Journal of clinical oncology, 2006-07, Vol.24 (21), p.3415-3422

2006

Link zum Volltext

Verfügbarkeit prüfen

Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Journal of clinical oncology, 2014-11, Vol.32 (31), p.3547-3552

2014

Link zum Volltext

Verfügbarkeit prüfen

Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Cancer, 2017-06, Vol.123 (12), p.2368-2375

2017

Link zum Volltext

Verfügbarkeit prüfen

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

Cancer, 2019-01, Vol.125 (2), p.290-297

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 572

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(539)
Mit Volltextzugriff
(481)

Publikationsform

Artikel
(571)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology Group

Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group

Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group

Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

Rhabdomyosarcoma: New Windows of Opportunity

The significance of margins in pediatric Non‐Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)

Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV

Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups

Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience—A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group

Regarding Beau

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial

Pooled Analysis of Phase II Window Studies in Children With Contemporary High-Risk Metastatic Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group

Aktive Filter

Suchergebnisse filtern